Asia-Pacific Electronic Patient-Reported Outcomes Market Forecast to 2031 - Regional Analysis - by Delivery Mode, Application, and End User

The Asia Pacific electronic patient-reported outcomes (ePROS) market was valued at US$ 157.62 million in 2023 and is expected to reach US$ 613.75 million by 2031; it is estimated to register a CAGR of 18.5% from 2023 to 2031.

Rising Adoption of Telehealth and Remote Monitoring Boosts Asia Pacific Electronic Patient-Reported Outcomes (ePROS) Market

The market for electronically reported patient outcomes (ePROs) is expected to experience lucrative opportunities with the rising adoption of telehealth and remote monitoring for clinical trials during the forecast period. Patients in remote or underserved areas can report real-time information from the comfort of their homes owing to telehealth and remote monitoring solutions, which increase accessibility of patient data. Health data can be continuously transmitted via remote monitoring devices, such as wearables and linked health systems. When coupled with ePRO systems, medical professionals receive detailed information regarding a patient's condition in real time, enabling more precise and regular interventions.

For example, Vivalink's integrated acute remote patient monitoring solution provides continuous and real-time monitoring of patient vitals, including live ECG, as well as information about vitals and biometrics, EPRO/ECOA/surveys, centralized data services, remote data collection, and patient adherence. The efficacy of ePRO systems is expanded by telehealth and remote monitoring developments, establishing them as a crucial element of patient-centered care.

Asia Pacific Electronic Patient-Reported Outcomes (ePROS) Market Overview

China is expanding its support for clinical trials of drugs, which has resulted in the acceleration of new drug development. According to The Annual Report on the Progress of Clinical Trials for New Drug Registration in China, a total of 3,358 clinical trials of medications were registered in the country in 2021; 3,410 in 2022; and 4,300 in 2023. This indicates a constant growth in clinical trials. In addition, 500 biological products were approved, with oncology, dermatology, and endocrinology being key therapy areas. In addition, the country has emerged as an increasingly attractive R&D outsourcing destination for international pharmaceutical companies with an aim to reduce their product timeline and cost to the market.

According to Clinical Trials Arena, the involvement of Western commercial companies in trial runs in the country has increased gradually from 100 trials per year in 2010 to ~350 trials in 2021. The surge in the number of clinical trials is creating a demand for ePROs to have real-time patient data and feedback during the trials, which also helps the manufacturer in the effective evaluation of the clinical trials. Moreover, increasing adoption of digital health technologies and supporting regulatory policies are expected to create ample opportunities for the electronic related patient outcomes (ePROS) market in the coming years.

Asia Pacific Electronic Patient-Reported Outcomes (ePROS) Market Revenue and Forecast to 2031 (US$ Million)

Asia Pacific Electronic Patient-Reported Outcomes (ePROS) Market Segmentation

The Asia Pacific electronic patient-reported outcomes (ePROS) market is categorized into delivery mode, application, end user, and country.

By delivery mode, the Asia Pacific electronic patient-reported outcomes (ePROS) market is bifurcated into cloud based and on-premises. The cloud based segment held a larger share of the Asia Pacific electronic patient-reported outcomes (ePROS) market share in 2023.

• In terms of application, the Asia Pacific electronic patient-reported outcomes (ePROS) market is segmented into oncology, respiratory, and others. The oncology segment held the largest share of the Asia Pacific electronic patient-reported outcomes (ePROS) market share in 2023.
• By end user, the Asia Pacific electronic patient-reported outcomes (ePROS) market is segmented into contract research organizations (CROs), pharmaceutical companies, and others. The pharmaceutical companies segment held the largest share of the Asia Pacific electronic patient-reported outcomes (ePROS) market share in 2023.
• Based on country, the Asia Pacific electronic patient-reported outcomes (ePROS) market is segmented into Japan, China, India, South Korea, Australia, and the Rest of Asia Pacific. China segment held the largest share of Asia Pacific electronic patient-reported outcomes (ePROS) market in 2023.

Assistek, Buddy Healthcare Ltd Oy, Castor, Clinical Ink Inc, Crucial Data Solutions, Curebase, Medable Inc, Medidata Solutions, Medrio, OpenClinica LLC, PatientIQ, Signant Health, Veeva Systems Inc, and Y-Prime LLC are some of the leading companies operating in the Asia Pacific electronic patient-reported outcomes (ePROS) market.

Reasons to Buy:

• Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Asia Pacific electronic patient-reported outcomes (ePROS) market.
• Highlights key business priorities to assist companies to realign their business strategies.
• The key findings and recommendations highlight crucial progressive industry trends in the Asia Pacific electronic patient-reported outcomes (ePROS) market, thereby allowing players across the value chain to develop effective long-term strategies.
• Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
• Scrutinize in-depth Asia Pacific market trends and outlook coupled with the factors driving the Asia Pacific electronic patient-reported outcomes (ePROS) market, as well as those hindering it.
• Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution.